Randomized in a 1:1 ratio, participants were treated with a maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). The cohort included adults with obesity ...

Currently, no treatments are available specifically for obesity-related HFpEF in the U.S. The multi-center trial used maximum tolerated dose of tirzepatide 5 mg, 10 mg or 15 mg once weekly.

This approval was based on results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated Tirzepatide (10 mg or 15 mg) for the treatment of moderate-to-severe OSA in adults with obesity, with ...

Higher doses of tirzepatide were particularly effective, with mean fasting insulin percent reductions of 27.76% (P =.003; 10 mg dose) and 37.0% (P <.00001; 15 mg dose) compared with placebo. All doses ...

Mounjaro (tirzepatide) is a prescription drug that ... The strengths in this chart are given in milligrams per milliliter of solution (mg/mL). Mounjaro comes as a liquid solution in a prefilled ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...